Burzynski Research Institute, Inc. (BZYR)
USD 0.05
(-1.63%)
USD 0.05
(-1.63%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -1.33 Million USD | -45.74% |
| 2023 | -916.29 Thousand USD | 6.18% |
| 2022 | -976.65 Thousand USD | 18.88% |
| 2021 | -1.2 Million USD | 26.34% |
| 2020 | -1.63 Million USD | 0.2% |
| 2019 | -1.63 Million USD | -1.59% |
| 2018 | -1.61 Million USD | -7.14% |
| 2017 | -1.5 Million USD | 24.96% |
| 2016 | -2 Million USD | 30.67% |
| 2015 | -2.89 Million USD | 32.3% |
| 2014 | -4.27 Million USD | 34.27% |
| 2013 | -6.49 Million USD | 9.2% |
| 2012 | -7.15 Million USD | -42.26% |
| 2011 | -5.03 Million USD | -4.15% |
| 2010 | -4.83 Million USD | 5.79% |
| 2009 | -5.12 Million USD | -13.39% |
| 2008 | -4.52 Million USD | -5.1% |
| 2007 | -4.3 Million USD | 6.48% |
| 2006 | -4.6 Million USD | 7.35% |
| 2005 | -4.96 Million USD | -13.27% |
| 2004 | -4.38 Million USD | 0.84% |
| 2003 | -4.42 Million USD | 14.59% |
| 2002 | -5.17 Million USD | -12.69% |
| 2001 | -4.59 Million USD | -4.82% |
| 2000 | -4.38 Million USD | 13.03% |
| 1999 | -5.03 Million USD | 29.29% |
| 1998 | -7.12 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -1.33 Million USD | -45.74% |
| 2024 Q4 | -362.9 Thousand USD | 16.19% |
| 2024 Q3 | -433.01 Thousand USD | -71.76% |
| 2024 Q2 | -252.1 Thousand USD | 12.28% |
| 2024 Q1 | -287.4 Thousand USD | -141.04% |
| 2023 Q2 | -215.91 Thousand USD | 6.83% |
| 2023 FY | -916.29 Thousand USD | 6.18% |
| 2023 Q4 | 700.29 Thousand USD | 377.19% |
| 2023 Q3 | -252.63 Thousand USD | -17.01% |
| 2023 Q1 | -231.73 Thousand USD | -35.61% |
| 2022 Q3 | -264.77 Thousand USD | -17.83% |
| 2022 Q1 | -316.28 Thousand USD | -106.5% |
| 2022 FY | -976.65 Thousand USD | 18.88% |
| 2022 Q4 | -170.87 Thousand USD | 35.46% |
| 2022 Q2 | -224.71 Thousand USD | 28.95% |
| 2021 Q3 | -264.32 Thousand USD | 19.55% |
| 2021 Q1 | -457.97 Thousand USD | -61.11% |
| 2021 Q4 | -153.16 Thousand USD | 42.06% |
| 2021 FY | -1.2 Million USD | 26.34% |
| 2021 Q2 | -328.54 Thousand USD | 28.26% |
| 2020 Q1 | -468.31 Thousand USD | -38.21% |
| 2020 Q4 | -284.25 Thousand USD | 39.74% |
| 2020 FY | -1.63 Million USD | 0.2% |
| 2020 Q2 | -410.22 Thousand USD | 12.4% |
| 2020 Q3 | -471.69 Thousand USD | -14.99% |
| 2019 Q4 | -338.83 Thousand USD | 22.93% |
| 2019 Q3 | -439.63 Thousand USD | 2.23% |
| 2019 FY | -1.63 Million USD | -1.59% |
| 2019 Q1 | -409.57 Thousand USD | -26.41% |
| 2019 Q2 | -449.67 Thousand USD | -9.79% |
| 2018 Q2 | -425.74 Thousand USD | 7.69% |
| 2018 FY | -1.61 Million USD | -7.14% |
| 2018 Q1 | -461.21 Thousand USD | -31.85% |
| 2018 Q3 | -401.12 Thousand USD | 5.78% |
| 2018 Q4 | -324.01 Thousand USD | 19.22% |
| 2017 FY | -1.5 Million USD | 24.96% |
| 2017 Q1 | -369.95 Thousand USD | 9.79% |
| 2017 Q3 | -383.13 Thousand USD | 4.65% |
| 2017 Q4 | -349.81 Thousand USD | 8.7% |
| 2017 Q2 | -401.81 Thousand USD | -8.61% |
| 2016 Q3 | -460.19 Thousand USD | 9.82% |
| 2016 Q1 | -624.52 Thousand USD | -1.24% |
| 2016 Q4 | -410.08 Thousand USD | 10.89% |
| 2016 FY | -2 Million USD | 30.67% |
| 2016 Q2 | -510.3 Thousand USD | 18.29% |
| 2015 FY | -2.89 Million USD | 32.3% |
| 2015 Q1 | -840.88 Thousand USD | -1.88% |
| 2015 Q4 | -616.88 Thousand USD | 12.82% |
| 2015 Q3 | -707.58 Thousand USD | 2.63% |
| 2015 Q2 | -726.69 Thousand USD | 13.58% |
| 2014 Q4 | -825.36 Thousand USD | 16.03% |
| 2014 Q2 | -1.1 Million USD | 18.46% |
| 2014 Q3 | -982.86 Thousand USD | 11.17% |
| 2014 FY | -4.27 Million USD | 34.27% |
| 2014 Q1 | -1.35 Million USD | 9.22% |
| 2013 Q4 | -1.49 Million USD | 2.28% |
| 2013 Q1 | -1.68 Million USD | 17.31% |
| 2013 Q2 | -1.79 Million USD | -6.79% |
| 2013 FY | -6.49 Million USD | 9.2% |
| 2013 Q3 | -1.52 Million USD | 14.74% |
| 2012 Q2 | -1.78 Million USD | -18.93% |
| 2012 FY | -7.15 Million USD | -42.26% |
| 2012 Q3 | -1.83 Million USD | -3.08% |
| 2012 Q4 | -2.03 Million USD | -10.42% |
| 2012 Q1 | -1.5 Million USD | -20.88% |
| 2011 Q4 | -1.24 Million USD | -2.65% |
| 2011 Q3 | -1.2 Million USD | -0.43% |
| 2011 Q1 | -1.37 Million USD | -5.13% |
| 2011 Q2 | -1.2 Million USD | 12.42% |
| 2011 FY | -5.03 Million USD | -4.15% |
| 2010 Q4 | -1.3 Million USD | -8.21% |
| 2010 Q2 | -1.19 Million USD | -6.7% |
| 2010 FY | -4.83 Million USD | 5.79% |
| 2010 Q1 | -1.11 Million USD | 7.73% |
| 2010 Q3 | -1.2 Million USD | -1.23% |
| 2009 Q3 | -1.34 Million USD | -4.02% |
| 2009 FY | -5.12 Million USD | -13.39% |
| 2009 Q1 | -1.28 Million USD | -0.27% |
| 2009 Q2 | -1.29 Million USD | -0.64% |
| 2009 Q4 | -1.21 Million USD | 9.63% |
| 2008 FY | -4.52 Million USD | -5.1% |
| 2008 Q4 | -1.27 Million USD | -24.22% |
| 2008 Q3 | -1.02 Million USD | 10.73% |
| 2008 Q1 | -1.06 Million USD | -2.0% |
| 2008 Q2 | -1.15 Million USD | -8.67% |
| 2007 Q1 | -1.15 Million USD | -8.11% |
| 2007 Q4 | -1.04 Million USD | -8.48% |
| 2007 Q3 | -958.92 Thousand USD | 16.33% |
| 2007 Q2 | -1.14 Million USD | 0.98% |
| 2007 FY | -4.3 Million USD | 6.48% |
| 2006 Q1 | -1.18 Million USD | 8.93% |
| 2006 Q2 | -1.3 Million USD | -10.51% |
| 2006 Q3 | -1.03 Million USD | 20.54% |
| 2006 Q4 | -1.07 Million USD | -3.03% |
| 2006 FY | -4.6 Million USD | 7.35% |
| 2005 Q2 | -1.21 Million USD | 6.25% |
| 2005 Q4 | -1.29 Million USD | -11.89% |
| 2005 Q3 | -1.16 Million USD | 4.2% |
| 2005 Q1 | -1.29 Million USD | -0.16% |
| 2005 FY | -4.96 Million USD | -13.27% |
| 2004 FY | -4.38 Million USD | 0.84% |
| 2004 Q1 | -1.06 Million USD | 12.7% |
| 2004 Q2 | -1.13 Million USD | -7.06% |
| 2004 Q3 | -888.16 Thousand USD | 22.09% |
| 2004 Q4 | -1.29 Million USD | -45.34% |
| 2003 Q3 | -1.1 Million USD | -9.21% |
| 2003 FY | -4.42 Million USD | 14.59% |
| 2003 Q1 | -1.07 Million USD | 11.93% |
| 2003 Q2 | -1.01 Million USD | 5.79% |
| 2003 Q4 | -1.21 Million USD | -10.02% |
| 2002 FY | -5.17 Million USD | -12.69% |
| 2002 Q4 | -1.22 Million USD | -0.31% |
| 2002 Q1 | -1.41 Million USD | -28.56% |
| 2002 Q2 | -1.31 Million USD | 6.87% |
| 2002 Q3 | -1.21 Million USD | 7.44% |
| 2001 Q4 | -1.1 Million USD | 9.3% |
| 2001 Q2 | -1.19 Million USD | -10.16% |
| 2001 Q1 | -1.08 Million USD | -4.33% |
| 2001 FY | -4.59 Million USD | -4.82% |
| 2001 Q3 | -1.21 Million USD | -1.6% |
| 2000 Q4 | -1.03 Million USD | -7.13% |
| 2000 FY | -4.38 Million USD | 13.03% |
| 2000 Q1 | -1.29 Million USD | 0.0% |
| 2000 Q2 | -1.07 Million USD | 17.18% |
| 2000 Q3 | -970.14 Thousand USD | 9.72% |
| 1999 FY | -5.03 Million USD | 29.29% |
| 1998 FY | -7.12 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arch Therapeutics, Inc. | -6.98 Million USD | 80.876% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 102.521% |
| Nascent Biotech, Inc. | -2.08 Million USD | 36.033% |
| Rebus Holdings, Inc. | -1.02 Million USD | -30.925% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.05% |
| Qrons Inc. | -789.34 Thousand USD | -69.182% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -111.166% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.867% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -221.42% |
| Skye Bioscience, Inc. | -37.64 Million USD | 96.453% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.219% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 79.693% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -388.45% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.319% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 53.83% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 26.646% |
| Mesoblast Limited | -87.95 Million USD | 98.482% |
| Marizyme, Inc. | -65.34 Million USD | 97.956% |
| Genus plc | 7.9 Million USD | 116.904% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 87.739% |
| Pharming Group N.V. | -10.54 Million USD | 87.339% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 38.454% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 64.007% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 84.9% |
| ContraFect Corporation | -65.15 Million USD | 97.95% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 72.669% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 22.694% |
| IMV Inc. | -36.48 Million USD | 96.34% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 83.431% |
| MultiCell Technologies, Inc. | -380.07 USD | -351264.485% |
| ONE Bio Corp. | 8.67 Million USD | 115.391% |
| Accustem Sciences Inc. | -3.74 Million USD | 64.354% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 97.417% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -5.39% |
| Q BioMed Inc. | -2.05 Million USD | 34.923% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 64.226% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 43.91% |
| Biomind Labs Inc. | -1.21 Million USD | -9.974% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.764% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 56.946% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 83.102% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 31.49% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -8817.141% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 91.586% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 77.044% |
| GB Sciences, Inc. | -1.36 Million USD | 1.927% |
| Alpha Cognition Inc. | -13.77 Million USD | 90.304% |
| HST Global, Inc. | -146.21 Thousand USD | -813.365% |
| CSL Limited | 2.64 Billion USD | 100.051% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 23.897% |
| Halberd Corporation | -79.67 Thousand USD | -1576.077% |
| Enzolytics Inc. | -2.17 Million USD | 38.653% |
| Agentix Corp. | -1.37 Million USD | 2.822% |
| Resverlogix Corp. | -3.61 Million USD | 63.007% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 57.892% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.547% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1462.685% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 119.285% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 66.387% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 55.87% |
| AVAX Technologies, Inc. | -6.41 Million USD | 79.178% |
| Zenith Capital Corp. | -10.59 Million USD | 87.397% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.601% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -5645.766% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 67.789% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2109.493% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 33.399% |
| Kadimastem Ltd | -3.3 Million USD | 59.623% |
| Helix BioMedix, Inc. | -1.05 Million USD | -26.454% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 65.032% |
| BioStem Technologies, Inc. | -8.48 Million USD | 84.258% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -202.566% |
| LadRx Corporation | 400.44 Thousand USD | 433.488% |
| Cell Source, Inc. | -5.32 Million USD | 74.904% |
| Regen BioPharma, Inc. | 1.02 Million USD | 230.476% |
| Regen BioPharma, Inc. | 1.02 Million USD | 230.476% |
| NovAccess Global Inc. | -4.76 Million USD | 71.999% |
| Affymax, Inc. | -14.42 Million USD | 90.742% |
| Itoco Inc. | -1.86 Million USD | 28.548% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 69.94% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 19.986% |
| Mobile Lads Corp. | -2.26 Million USD | 40.996% |
| CytoDyn Inc. | -49.84 Million USD | 97.321% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1589.713% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -485.389% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -41.836% |
| SYBLEU INC | -180.3 Thousand USD | -640.655% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 17.195% |
| International Stem Cell Corporation | -131 Thousand USD | -919.413% |
| Bioxytran, Inc. | -4.28 Million USD | 68.798% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2360.626% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 47.221% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 97.222% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 36.829% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -71.015% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 57.846% |
| Neutra Corp. | -233.46 Thousand USD | -472.005% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 93.419% |
| PureTech Health plc | -65.69 Million USD | 97.967% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 93.721% |
| IXICO plc | -1.17 Million USD | -13.364% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 86.547% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.662% |
| CSL Limited | 2.64 Billion USD | 100.051% |
| Cellectis S.A. | -103.17 Million USD | 98.706% |